Navigation Links
Nobel Laureate Finds an Alternate Way to Manufacture Anti-Flu Drug

US researcher and a Nobel laureate hopes to manufacture plentiful anti-flu drugs at a cheaper cost. Tamiflu is the anti-flu drug and Elias Corey has work out the method while relaxing at home on a weekend. // The Swiss manufacturer Roche has manufactured the drug and given it to World Health Organization to prevent any outbreak of the disease. But the starting material (shikimic acid) for the production cycle is a compound extracted from the plant star anise. This is grown in mountain provinces in southwest China.

The compound at its heart has a ring of carbon molecules that makes a very particular template on which the rest of the drug can be built. The plant has to be harvested once a year, and Tamiflu production is now taking up most of the crop. Professor Corey won the Nobel Prize for Chemistry in 1990 for his successes in devising lab-bench approaches to synthesizing natural compounds. He used an old approach were mixtures of the useful and useless forms of complex molecules are formed, and then separated later. But it is a wasteful and time-consuming process. Hence he came to the rescue of the Roche's problem. In just about eight weeks time the whole process had been worked through and refined, and the product compared with genuine Tamiflu. The entire process elaborated in the online edition of the Journal of the American Chemical Society.


'"/>




Page: 1

Related medicine news :

1. Nobel Prize for Medicine shared by Three scientists
2. Stem cell research- now Nobel Laureates join the debate
3. Nobel laureates in chemistry
4. Nobel Prize for Medicine
5. Cholesterol Mystery Solved By Nobel Laureates
6. Nobel For Ulcer-Defying Aussie Scientists
7. Aussie Nobel Prize Winners Receive Their Awards
8. Dutch chemical group Akzo Nobel Develops A New Bird Flu Vaccine
9. Two Americans Share 2006 Nobel Medicine Prize
10. Nobel Prize – a ‘near miss’ for Indian Scientist coule
11. Nobel Prize for Gene ‘Silencing
Post Your Comments:
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begin...l/ -- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ...ced today that its subsidiary has commenced commer...psules USP product in the 40mg,strength from its D...on,with the launch, Watson has 180 days of marketi...
(Date:7/25/2008)...AUMBURG, Ill., July 25 /PRNewswire/ -- Sagent Phar...maceutical company, today announced that it,has la...antiarrhythmic,indicated for the treatment and pro...llation and hemodynamically unstable ventricular,t...ular heart beat.,Sagent,s amiodarone HCl injection...
(Date:7/25/2008)...LSBAD, Calif., July 25 /PRNewswire/ -- AutoGenomic...ration statement on Form S-1 with the,Securities a...itial public,offering of shares of its common stoc...red, all of which are expected to be offered by,Au...ring, have not yet been,determined., J.P. Morgan ...
(Date:7/25/2008)... New program delivers immediate ... [24-hour telephone access to language interprete...ing multilingual solutions. , ... LLE® http://www.lle-inc.com/index.html [(L...ovider of interpretation, translation, and languag...
Breaking Medicine News(10 mins):Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 2Health News:LLE Launches Over-the-Phone Interpretation OPI Easy Switch Program 3
...ide a bridge to a transplant.Heart failure is char...le to pump blood around the body. Till now, it has...sible - with the only real cure being a transplant...e (LVAD) is a mechanical pump which is used to sup...
...lly to the heart.Improvements in heart disease ris...smoking. It's known that smoking increases the ris...oxide in cigarette smoke,// which raises cholester...ther heart disease risk factors. Each 1% increase ...
...e more likely to have a specific variant of a bloo... tests on 500 men who had died suddenly, many of w... men younger than 55, a gene variant known as HPA-... common than in the general population.// The gen...
...skin could be better than white at fending off fun... James Mackintosh says it could explain why dark s...al environments. A popular theory on why darker sk... skin in others, is that// the extra melanin in da...
Other Medicine News:
(Date:7/23/2008)...TTLE, July 23 /- Sound Pharmaceutical...ication with the FDA for the clinical,testing of a...tion of,chemotherapy induced hearing loss or ototo...005, will be tested in advanced stage lung cancer,...um based chemotherapy.,This marks the second devel...
(Date:7/23/2008)...TTLE, July 23 /- Dendreon C...t expects the Independent Data,Monitoring Committe...lysis,of overall survival relating to the Company,...Carcinoma Treatment, also known as D9902B) clinica... the Company,s investigational,active cellular imm...
(Date:7/22/2008)...est awards under Therapeutics Development Initiati...ions to 23; next deadline January 20,2009, NEW Y... its mission to,speed delivery of transformative t...Michael J. Fox Foundation for Parkinson,s Research...industry research teams. The awards,were granted u...
(Date:7/22/2008)...Geoffrey Allan Will Stress the Importance to Patie...ics Approval Pathway, RICHMOND, Va., July 22 /PRN...) a developer of follow-on biologics and biopharma....D., CEO of Insmed, will present at a,Congressiona...he,significant need for establishing an approval p...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 2Insmed CEO to Present at Congressional Briefing on Follow-On Biologics 3Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD 385 1Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD 385 2Adult offspring of parents with PTSD have lower cortisol levels 381 1Adult offspring of parents with PTSD have lower cortisol levels 381 24 Star Gen Barry McCaffrey Former U S Drug Czar to Address National Drug Crisis Keynote Grand Opening of New Allenwood PA National Model Detox C 377 14 Star Gen Barry McCaffrey Former U S Drug Czar to Address National Drug Crisis Keynote Grand Opening of New Allenwood PA National Model Detox C 377 2American Chemical Societys Weekly Presspac Aug 29 2007 218 1American Chemical Societys Weekly Presspac Aug 29 2007 218 2American Chemical Societys Weekly Presspac Aug 29 2007 218 3American Chemical Societys Weekly Presspac Aug 29 2007 218 4American Chemical Societys Weekly Presspac Aug 29 2007 218 5American Chemical Societys Weekly Presspac Aug 29 2007 218 6American Chemical Societys Weekly Presspac Aug 29 2007 218 7American Chemical Societys Weekly Presspac Aug 29 2007 218 8
...NA, Calif.--(BUSINESS WIRE)--Mar 20, 2007 - Caland...mpany and a,majority-owned subsidiary of Arrowhead... publication in the Proceedings of the,National Ac...f the,NAS, of the first non-human primate study to... siRNA therapeutic candidate that is a,nanoparticl...
...FIELD, N.J., March 20, 2007 /PRNewswire-FirstCall/...as shown potential to,act as a potent payload in a...o the latest edition of the Handbook of Therapeuti...ews immunotoxins, Susanna,Rybak, Ph.D. summarizes ...ty and potency of ONCONASE improves in a number of...
Other Medicine Technology:Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 2Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 3Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 4Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal 5Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4
Stat Fax 2600 is fully automatic microplate washer.
The Microtech Microplate Washer (220 V) is a flexible and ultra compact microplate washer. The system offers a wide choice of washing functions and sequences designed to handle most any microplate ap
PW 41 is a powerful, compact and programmable 2 x 8-channel microplate washers/aspirators, with built-in vacuum and dispensing pumps. Dispense and aspirate head heights ,are user-adjustable, with v
LHW is a solid made, manual plate washer for low throughput use. Separate valves for dispense and aspirate function ensure proper washing results. LHW8 comes complete with a stand and all necessary t
Medicine Products: